Fig. 5

Tumor-specific cancer therapy in vivo. a, b CT26 tumors bearing mice were divided into four groups (n = 5) and received the following administration (1) None treatment as the control group; (2) Nr-PtMn-1 (i.t.); (3) R-PtMn-1 (i.t.); (4) R-PtMn-1 (i.v.). a Tumor growth curves of different groups. b Tumor weight of each group on the 14th day post-treatment. c, d 4T1 tumors bearing mice were divided into two groups (n = 5) and received the following administration (1) None treatment as the control group; (2) R-PtMn-1 (i.v.). c Tumor growth curves of different groups. d Tumor weight of each group on the 14th day post-treatment. e–h Nr-PtMn-1 or R-PtMn-1 was locally injected into the tumor, followed by tissue staining via DCFH-DA, or TUNEL, respectively. The representative tumors were collected from the mice in each group for various stainings, such as DCFH-DA staining for ROS generation; and TUNEL and H&E staining for apoptosis and necrosis. e Representative confocal images of DCFH-DA CT26 tumor slice, as well as TUNEL or H&E-stained tumor slice. f Representative confocal images of DCFH-DA or liperfluo-stained 4T1 tumor slice, as well as TUNEL or H&E-stained tumor slice. g Quantification of fluorescence intensity for DCFH-DA from (e). h Quantification of fluorescence for DCFH-DA from (f). The statistical analysis was performed in contrast to the control group (*p < 0.05, **p < 0.01, ***p < 0.001, t-test)